Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression
Open Access
- 1 February 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 95 (3) , 837-845
- https://doi.org/10.1182/blood.v95.3.837.003k08_837_845
Abstract
Myelopoietins (MPOs) constitute a family of engineered, chimeric molecules that bind and activate the IL-3 and G-CSF receptors on hematopoietic cells. This study investigated the in vivo hematopoietic response of rhesus monkeys administered MPO after radiation-induced myelosuppression. Animals were total body irradiated (TBI) in 2 series, with biologically equivalent doses consisting of either a 700 cGy dose of Cobalt-60 (60Co) γ-radiation or 600 cGy, 250 kVp x-irradiation. First series: On day 1 after 700 cGy irradiation, cohorts of animals were subcutaneously (SC) administered MPO at 200 μg/kg/d (n = 4), or 50 μg/kg/d (n = 2), twice daily, or human serum albumin (HSA) (n = 10). Second series: The 600 cGy x-irradiated cohorts of animals were administered either MPO at 200 μg/kg/d, in a daily schedule (n = 4) or 0.1% autologous serum (AS) , daily, SC (n = 11) for 23 days. MPO regardless of administration schedule (twice a day or every day) significantly reduced the mean durations of neutropenia (absolute neutrophil count [ANC] < 500/μL) and thrombocytopenia (platelet < 20 000/μL) versus respective control-treated cohorts. Mean neutrophil and platelet nadirs were significantly improved and time to recovery for neutrophils (ANC to < 500/μL) and platelets (PLT < 20 000/μL) were significantly enhanced in the MPO-treated cohorts versus controls. Red cell recovery was further improved relative to control-treated cohorts that received whole blood transfusions. Significant increases in bone marrow-derived clonogenic activity was observed by day 14 after TBI in MPO-treated cohorts versus respective time-matched controls. Thus, MPO, administered daily was as effective as a twice daily schedule for multilineage recovery in nonhuman primates after high-dose, radiation-induced myelosuppression.Keywords
This publication has 31 references indexed in Scilit:
- Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.Journal of Clinical Investigation, 1996
- Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice.The Journal of Experimental Medicine, 1994
- Growth factors as survival factors: Regulation of apoptosisBioEssays, 1994
- Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents.The Journal of Experimental Medicine, 1992
- Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosisNature, 1990
- Preclinical studies on synergistic effects of IL-1, IL-3, G-CSF and GM-CSF in cynomolgus monkeysThe International Journal of Cell Cloning, 1990
- GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATIONThe Lancet, 1989
- Human IL-3 and GM-CSF Act Synergistically in Stimulating Hematopoiesis in PrimatesScience, 1988
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988
- Effects of Recombinant Human Granulocyte–Macrophage Colony-Stimulating Factor in Patients with Myelodysplastic SyndromesNew England Journal of Medicine, 1987